MEDI8852

DRUG4 trials

Sponsors

MedImmune LLC

Conditions

InfluenzaInfluenza - Type A Strains

Phase 1

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

CompletedNCT02350751

MedImmune LLCInfluenza

Start: 2015-01-31End: 2015-06-30Updated: 2015-07-13

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

CompletedNCT02603952

MedImmune LLCInfluenza

Start: 2015-12-07End: 2016-12-09Updated: 2018-06-08

Phase 2

Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.

WithdrawnNCT03028909

MedImmune LLCInfluenza - Type A Strains

Start: 2017-07-24End: 2019-07-26Updated: 2019-03-14

Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

WithdrawnNCT03903718

MedImmune LLCInfluenza

Start: 2020-04-03End: 2020-10-09Updated: 2020-01-18

Related Papers

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.

2019-01-0968 citations

Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.

2018-10-2455 citations

A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.

2017-08-2318 citations